\
&
Contact us
\
&
Contact us
As the European Commission's science and knowledge service, the Joint Research Centre's mission is to support EU policies with independent, evidence-based, scientific and technical support throughout the whole policy cycle.
Located across five different countries, the JRC hosts specialist laboratories and unique research facilities and is home to thousands of scientists working to support the EU policy.
Working in close cooperation with policy Directorates-General, the JRC addresses key societal challenges while stimulating innovation through developing new methods, tools and standards, and sharing its know-how with the Member States, the scientific community and international partners. The JRC collaborates with over a thousand organisations worldwide whose scientists have access to many JRC facilities through various collaboration agreements. The JRC is a key player in supporting successful investment in knowledge and innovation foreseen by the Horizon 2020 Work Programme.
manhei.to@fwo.be
+32 2 550 15 55
Missions New European Bauhaus Horizon Europe JRC
Applications are now open for the first New European Bauhaus Prizes, launched by Commissioner Ferreira and Commissioner Gabriel during the New European Bauhaus Conference. The New European Bauhaus Initiative has the ambition to make the Green Deal a cultural, human-centred and positive, tangible experience. To accelerate the green transition, con... read more
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
